Publication Archives - WuXi Biology

Native Mass Spectrometry Facilitates Validation of DEL Hits

Hit validation is a crucial step in drug discovery based on DNA-encoded libraries (DEL). Rapid and accurate resynthesis of compounds,...

Discovery of a Novel CD39 Inhibitor by DEL Screening

The ATP-adenosine pathway plays a crucial role in regulating immune responses, including those involved in combating tumors. CD39 is an...

Developing Animal Gout Models

Gout is a common type of inflammatory arthritis caused by elevated uric acid levels in the blood. When uric acid...

DNA-Compatible Huisgen Cycloaddition

In our latest publication, WuXi AppTec scientists introduce two new methods that utilize readily accessible aldehydes to create substituted isoxazolines...

Rational Design and Optimization of a Potent IDO1 PROTAC

Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that metabolizes tryptophan, and its activity can lead to immunosuppression, thereby allowing tumors...

Development, Characterization, and Therapeutic Utility of Paclitaxel-Resistant Models

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The development of targeted therapies...

DEL Screening to Discover Small Molecule Ligands for RNA

RNA-targeted therapeutics are highly intriguing due to their unique physiological properties and novel modes of action in drug R&D. Developing...

Targeting FAK Improves the Tumor Uptake of ADCs

Antibody-drug conjugates (ADCs), exemplified by HER2-targeted Enhertu and TROP2-targeted Trodelvy, have demonstrated significant therapeutic potential in cancers. However, a subset...

Discovery of a Selective BET Inhibitor for Treating Osteoarthritis

Bromodomain and extra-terminal domain (BET) family proteins are key regulators of gene transcription and have been implicated in a wide...

Knowledge Library